Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases

Timothy M. Pawlik, Michael A. Choti

Research output: Contribution to journalArticle

Abstract

Following resection of hepatic colorectal metastases, there are few criteria for predicting which patients have more aggressive disease and are, therefore, more likely to experience recurrence and reduced survival. Traditionally, primary tumor stage, preoperative carcinoembryonic antigen level, time from primary tumor treatment to diagnosis of hepatic metastases (disease-free interval), hepatic tumor size, number of hepatic metastases, and presence of extrahepatic disease have been reported to be predictors of survival after resection. However, the data regarding the prognostic importance of these clinicopathologic factors are inconsistent and conflicting. Therefore, conventional clinicopathologic factors may be inadequate for the purposes of prognostication. More recently, there has been increased interest in identifying biologic indicators that may help better define patients at risk for recurrence after hepatic resection for colorectal metastases. Recent studies have shown that proliferation markers such as p53 expression, tritiated thymidine uptake, thymidylate synthase, Ki-67, and human telom-erase reverse transcriptase may be better predictors of outcome after resection of hepatic colorectal metastases. Moreover, tumor response to preoperative chemotherapy may also prove to be a useful predictor of outcome following liver resection for colorectal metastases.

Original languageEnglish (US)
Pages (from-to)85-93
Number of pages9
JournalCurrent Colorectal Cancer Reports
Volume2
Issue number2
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Neoplasm Metastasis
Liver
Neoplasms
Recurrence
Thymidylate Synthase
Survival
RNA-Directed DNA Polymerase
Carcinoembryonic Antigen
Thymidine
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology

Cite this

Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases. / Pawlik, Timothy M.; Choti, Michael A.

In: Current Colorectal Cancer Reports, Vol. 2, No. 2, 03.2006, p. 85-93.

Research output: Contribution to journalArticle

@article{7cb171642d154793932eff1d4bd7514c,
title = "Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases",
abstract = "Following resection of hepatic colorectal metastases, there are few criteria for predicting which patients have more aggressive disease and are, therefore, more likely to experience recurrence and reduced survival. Traditionally, primary tumor stage, preoperative carcinoembryonic antigen level, time from primary tumor treatment to diagnosis of hepatic metastases (disease-free interval), hepatic tumor size, number of hepatic metastases, and presence of extrahepatic disease have been reported to be predictors of survival after resection. However, the data regarding the prognostic importance of these clinicopathologic factors are inconsistent and conflicting. Therefore, conventional clinicopathologic factors may be inadequate for the purposes of prognostication. More recently, there has been increased interest in identifying biologic indicators that may help better define patients at risk for recurrence after hepatic resection for colorectal metastases. Recent studies have shown that proliferation markers such as p53 expression, tritiated thymidine uptake, thymidylate synthase, Ki-67, and human telom-erase reverse transcriptase may be better predictors of outcome after resection of hepatic colorectal metastases. Moreover, tumor response to preoperative chemotherapy may also prove to be a useful predictor of outcome following liver resection for colorectal metastases.",
author = "Pawlik, {Timothy M.} and Choti, {Michael A.}",
year = "2006",
month = "3",
doi = "10.1007/s11888-006-0007-x",
language = "English (US)",
volume = "2",
pages = "85--93",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "2",

}

TY - JOUR

T1 - Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases

AU - Pawlik, Timothy M.

AU - Choti, Michael A.

PY - 2006/3

Y1 - 2006/3

N2 - Following resection of hepatic colorectal metastases, there are few criteria for predicting which patients have more aggressive disease and are, therefore, more likely to experience recurrence and reduced survival. Traditionally, primary tumor stage, preoperative carcinoembryonic antigen level, time from primary tumor treatment to diagnosis of hepatic metastases (disease-free interval), hepatic tumor size, number of hepatic metastases, and presence of extrahepatic disease have been reported to be predictors of survival after resection. However, the data regarding the prognostic importance of these clinicopathologic factors are inconsistent and conflicting. Therefore, conventional clinicopathologic factors may be inadequate for the purposes of prognostication. More recently, there has been increased interest in identifying biologic indicators that may help better define patients at risk for recurrence after hepatic resection for colorectal metastases. Recent studies have shown that proliferation markers such as p53 expression, tritiated thymidine uptake, thymidylate synthase, Ki-67, and human telom-erase reverse transcriptase may be better predictors of outcome after resection of hepatic colorectal metastases. Moreover, tumor response to preoperative chemotherapy may also prove to be a useful predictor of outcome following liver resection for colorectal metastases.

AB - Following resection of hepatic colorectal metastases, there are few criteria for predicting which patients have more aggressive disease and are, therefore, more likely to experience recurrence and reduced survival. Traditionally, primary tumor stage, preoperative carcinoembryonic antigen level, time from primary tumor treatment to diagnosis of hepatic metastases (disease-free interval), hepatic tumor size, number of hepatic metastases, and presence of extrahepatic disease have been reported to be predictors of survival after resection. However, the data regarding the prognostic importance of these clinicopathologic factors are inconsistent and conflicting. Therefore, conventional clinicopathologic factors may be inadequate for the purposes of prognostication. More recently, there has been increased interest in identifying biologic indicators that may help better define patients at risk for recurrence after hepatic resection for colorectal metastases. Recent studies have shown that proliferation markers such as p53 expression, tritiated thymidine uptake, thymidylate synthase, Ki-67, and human telom-erase reverse transcriptase may be better predictors of outcome after resection of hepatic colorectal metastases. Moreover, tumor response to preoperative chemotherapy may also prove to be a useful predictor of outcome following liver resection for colorectal metastases.

UR - http://www.scopus.com/inward/record.url?scp=34547193891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547193891&partnerID=8YFLogxK

U2 - 10.1007/s11888-006-0007-x

DO - 10.1007/s11888-006-0007-x

M3 - Article

VL - 2

SP - 85

EP - 93

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 2

ER -